검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AMG 706 |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Breast Neoplasms |
Overview Indication | Advanced Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeted tyrosine kinase inhibitor of VEGF, PDGF and stem cell factor receptor |
MoA Biomarker | biomarker development would be useful in developing future clinical trials in NET to better tailor individual |
PK/PD Species | Rat, ration, migration, xenograft |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat, ration, migration, xenograft |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.. Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer.Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a clinical trial.Improvements in biomarker… |
Clinical Primary efficacy | ORR 33% |
Clinical ORR | 33% |
Clinical Result source | ClinicalTrials.gov NCT00094835 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AMG 706 |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Breast Neoplasms |
Overview Indication | Advanced Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeted tyrosine kinase inhibitor of VEGF, PDGF and stem cell factor receptor |
MoA Biomarker | biomarker development would be useful in developing future clinical trials in NET to better tailor individual |
PK/PD Species | Rat, ration, migration, xenograft |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat, ration, migration, xenograft |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.. Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer.Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a clinical trial.Improvements in biomarker… |
Clinical Primary efficacy | ORR 33% |
Clinical ORR | 33% |
Clinical Result source | ClinicalTrials.gov NCT00094835 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교